SDZ-220-581 (SDZ-220581; SDZ220581) is a novel and potent competitive antagonist of NMDA glutamate receptor subtype(pKi= 7.7) with the potential to be used for Parkinson’s disease.

SDZ 220-581 Ammonium salt (SDZ-220581; SDZ220581) is a novel and competitive antagonist of NMDA glutamate receptor subtype (pKi= 7.7) with the potential to be used for Parkinson’s disease.

LY3130481 (also known as CERC-611) is a novel and potent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist t that is dependent upon transmembrane AMPA receptor regulatory protein (TARP) γ-8, it selective inhibits AMPA/TARP γ-8 with an IC50 of 65 nM.

1-BCP is a centrally active drug that modulates AMPA receptor gated currents. 1-BCP is a memory-enhancing agent.

Naspm 3HCl (1-Naphthylacetyl spermine trihydrochloride), the trihydrochloride salt of Naspm, is a synthetic analog of Joro spider toxin and a calcium permeable AMPA (CP-AMPA) receptors antagonist.

QNZ46 is a novel non-competitive and NR2C/NR2D-selective NMDA receptor antagonist with IC50 values of 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively.

Noopept, formerly known as Omberacetam, is an AMPA receptor modulator potentially for the treatment of cognitive deficits.

WAY-303290 (WAY303290) is a novel and potent inhibitor of pY binding site of tyrosine kinase p56lck SH2 domain.

Coluracetam (also known as MKC-231 and BCI-540) is a novel choline uptake enhancer.

IC87201 is an inhibitor of PSD95-nNOS protein-protein interactions.